Pharmacoecomonic study of oral antidiabetic drugs available in Indian pharmaceutical market
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20232563Keywords:
Diabetes mellitus, Oral hypoglycemic drugs, ComplianceAbstract
Background: Diabetes mellitus is a metabolic disorder requiring lifelong medication which further adds to comorbidity. Cost of the drug pays an important role in adherence and compliance to the treatment. There is a wide variation in prices of oral hypoglycemic drugs available in Indian pharmaceutical market. Aims and objectives of the study was planned to evaluate cost of oral antidiabetic drugs of various brands currently available in Indian market either as single drug or in combination.
Methods: Cost of antidiabetic medications manufactured by various pharmaceutical companies in the same strength and dosage form was obtained from the price list provided by various pharmaceutical companies in current index of medical specialties December 2022-March2023. The cost ratio and percentage price variation for each formulation was calculated and analyzed.
Results: Among single antidiabetic drugs, Tab. Metformin 500 mg shows highest percentage price variation (809%) and highest cost ratio (9.09). Among fixed dose combinations, Tab. Glibenclamide 5 mg + Tab. Metformin 500 mg shows highest percentage price variation 300.8% and highest cost ratio 4.
Conclusions: Our study shows that there is high price variation for oral anti diabetics. It is important to bring awareness about wide variation in prices so that drug cost can be reduced and made affordable to common man which plays major role in compliance of patient.
References
Aran KR, Singh S, Gupta GD. Cost variation analysis of oral antidiabetic drugs currently available in the Indian pharmaceutical market. Nat Prod Chem Res. 2022;10:1-3.
Acharya KG, Shah KN, Solanki ND, Rana DA. Evaluation of antidiabetic prescriptions, cost and adherence to treatment guidelines: A prospective, cross sectional study at a tertiary care teaching hospital. J Basic Clin Pharm. 2013;4:82-7.
Abidi A, Rizvi DA, Ahmad A. Pharmacoeconomic and drug utilization study of antidiabetic therapy in a tertiary care teaching hospital of Northern India. Asian J Pharm Clin Res. 2016;9:371-5.
Shyam S, Mahanthegowda BD. A cost variation analysis of various brands of oral anti-diabetic drugs currently available in Indian pharmaceutical market. Int J Basic Clin Pharmacol. 2020;9: 1253-7.
Rajadnya VA. Cost comparisions of five leading brands of the Antiplatelet drug, Clopidogrel, available in an Indian town. Int J Basic Clin Pharmacol. 2019;8: 1734-7.
Koenig-Oberhuber V, Filipovic M. New antiplatelet drugs and new oral anticoagulants. Br J Anaesth. 2016; 117(2):74-84.
Sahay A, Jaikumar S. Does pharmaceutical price regulation result in greater access to essential medicines? Study of impactof drug price control order on sales volume of drugs in India. Indian Inst Manage Ahmedabad. 2014;34:64-5.
Balarajan Y, Selvaraj S, Subramanian SV. Health care and equity in India. Lancet. 2011;377:505-15.
Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India. 2004;17:80-3.
Nair MK, Neha MS. Cost variation analysis of antihypertensive drugs acting through renin angiotensin aldosterone axis modulation. Int J Basic Clin Pharmacol. 2017;6:1085-9.
Mehani R, Sharma P. Cost variation analysis of oral antidiabetic drugs. Int J Basic Clin Pharmacol. 2018; 7:1709-14.
Arya N, Agrawal S, Agrawal M. A study of the cost analysis of various oral antihypertensive drugs available in Indian market. Int J Basic Clin Pharmacol. 2019;8:1850-4.
Chawan VS, Gawand KV, Badwane SV. Cost analysis of oral hypolipidemic agents available in India. Int J Basic Clin Pharmacol. 2014;3:954-7.
Wadagbalkar P, Patel P, Raipurkar SV. Cost variation analysis of ACE inhibitors in India. Int J Basic Clin Pharmacol. 2017;6:1522-5.
Amaravati RVC, Kandra NV. Cost analysis of oral hypoglycemic agents available in Indian pharmaceutical market. Nat J Physiol Pharma Pharmacol. 2023;13(7): 01-05.
